<div id="readability-page-1">Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shares are up 2.2% to trade at $7.06 at last check. The company announced last week it filed a Biologics License Application with the U.S. Food and Drug Administration (FDA) for isidolimab, its antibody-based treatment for patients with pustular psoriasis. The stock is extending last week's move above the $7 level, and marked a fresh two-year high of $7.25 right out of the gate. VNDA toppled resistance at $5.50 earlier this month after spending November firmly below this level. So far this year, the equity has added over 47%. Short interest makes up 8.5% of the security's total available float, with 4.6 million shares sold short and bearish bets climbing nearly 20% over the last two weeks. At the stock's average pace of trading, it would take nearly seven days for shorts to buy back their positions. Drilling down to today's options activity, 2,267 calls have crossed the tape -- double the intraday average volume -- compared to only 65 puts. The most popular contract is the January 16, 2026 8-strike call.</div>

Vanda制药

Vanda 制药公司（NASDAQ:VNDA）股价上涨 2.2%，至 7.06 美元，此前该公司向 FDA 提交了生物制剂许可申请，申请治疗脓疱型银屑病的药物 isidolimab。该股创下两年高点 7.25 美元，今年上涨超过 47%。空头头寸占流通股的 8.5%，看跌押注增加。期权活动显示有 2,267 份看涨期权，交易量是平均水平的两倍，其中 2026 年 1 月 16 日的 8 美元行权价看涨期权最受欢迎

Vanda 制药的股票因提交 FDA 申请而上涨